In 2020 , Hua Medicine and Bayer announced a strategic partnership and commercial agreement aimed at bringing the innovative drug Dorzagliatin, a first— in-class dual glucokinase activator, to the Chinese market. This agreement is an important step not only for the participants in the deal, but also for the entire healthcare system in China, where millions of patients face daily difficulties in controlling type 2 diabetes.
Combining expertise and resources
Hua Medicine is a Shanghai-based biotech company focused on developing revolutionary treatments for metabolic diseases. Their key development, Dorzagliatin, represents a fundamentally new approach to diabetes management by restoring glucose regulation at the liver and pancreas levels.
Bayer, in turn, has an extensive network in China and a strong infrastructure in the areas of marketing, medical education and drug distribution. Thanks to this, the partnership allows us to speed up patients ‘ access to innovative therapies.
The essence of the agreement
Under the terms of the agreement:
- Hua Medicine reserves the rights of the Registration Certificate Holder (MAH) and is also responsible for the production, supply and logistics of Dorzagliatin.
- Bayer receives exclusive rights for commercial promotion of the drug in China and assumes the functions of medical support, promotion and informing the medical community.
- A system of phased payments and incentive bonuses is also provided, reflecting the high interest of both parties in the success of the project.
Value for patients and the healthcare system
This collaboration opens up new horizons for the treatment of type 2 diabetes:
- Faster access to an innovative drugthat can affect the very cause of the disease, not just the symptoms.
- Expanding therapeutic options for doctors, especially in cases where other drugs do not give the desired effect.
- The opportunity for millions of patients in China to receive a treatment that combines efficacy, safety, and an innovative mechanism of action.
The partnership combines the scientific potential and clinical expertise of Hua Medicine with the commercial power and expertise of Bayerto ensure a sustainable outcome for the healthcare system in the long term.
Long-term strategy
This agreement goes beyond simple licensing. It has become an example of how collaborative efforts can transform an entire therapeutic field. For both companies, this is not just a deal — it’s an alliance that aims to improve the lives of millions of peoplesuffering from diabetes.
Dorzagliatin, in turn, was able to gain a strong position in the market through strategic outreach, training of doctors and public awareness. Bayer, with its extensive experience in large-scale projects, enhances the penetration of the drug into medical practice.
The Hua Medicine-Bayer partnership is a strategic, mutually beneficial, and patient-centered agreement that has the potential to transform the treatment of type 2 diabetes in China. It demonstrates how innovation and global expertise can work in synergy to create real improvements in Dorsagliatin healthcare. . it has received strong support for successful entry into the market, and patients-a chance for a new era in the treatment of diabetes.
Sources:
https://www.huamedicine.com
https://global.chinadaily.com.cn
https://www.apac-business.com
https://www.labiotech.eu
